A genome-editing technique known as prime editing holds potential for treating many diseases by transforming faulty genes into functional ones. However, the process carries a small chance of inserting ...

Prime Medicine, a biotech company that set out to use its more precise approach to gene editing to develop new one-time treatments for rare diseases, is expanding its scope to more prevalent ...

Researchers at the Francis Crick Institute have demonstrated that a genetic method called "pooled prime editing" can screen hundreds of variants in a gene at once and identify which variants affect ...

A new genome editing tool—minimal versatile genetic perturbation technology (mvGPT)—can achieve simultaneous and orthogonal gene editing and gene regulation in human cells. The coming together of ...

A team of researchers at the Broad Institute, led by gene-editing pioneer David Liu, has developed a new genome-editing strategy that could potentially lead to a one-time treatment for multiple ...

Scientists use a precise form of gene editing called prime editing to correct the most common genetic mutations that cause alternating hemiplegia of childhood, a rare and severe neurological disorder ...

Infants born with alternating hemiplegia of childhood (AHC) begin experiencing episodes of paralysis and seizures by the time they are a few months old, followed by developmental delays and ...

A 3D illustration of a transfer RNA molecule hovering over a messenger RNA. Transfer RNA acts as an adaptor to convert messenger RNA codons into amino acids during protein synthesis. Credit: ...

While researchers have long appreciated the enormous potential of genome editing to treat disease, applications of these technologies in humans have historically been limited by safety concerns. Even ...

Initiate Hold on Prime Medicine due to pending Phase 1/2 CGD readout in 2025 and Wilson’s Disease IND filing in 2026, focusing on safety and mechanistic editing. Await six-month durability data in ...